Olympus Corporation

Company Presentation

August 2026 Ver. 3

Disclaimer:

- Any content or information (“Content”) presented herein is illustrative in nature and does not guarantee or represent specific information, outcomes or results.
- Under no circumstances shall Olympus or its employees, consultants, agents or representatives be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the Content or any use thereof.
- Some of the products and/or technology shown herein are future technology concepts that are under development and are not presently available in all countries, including not being available in the United States. There is no time period established as to when or if these products and/or technologies will be available in such markets, including the United States. The safety and effectiveness of these products and technologies and/or the use of these products and technologies have not yet been established in the United States market.
- The content of this presentation may contain off-label information and is intended only for the discussion of the potential future use of new technologies and products. Specifications, design, and accessories are subject to change without any notice or obligation on the part of the manufacturer. There is no time period established as to when or if these products and/or technologies will be available in the United States or other countries.
- Certain statements contained in this presentation are forward-looking statements based on current expectations, estimates, forecasts, and assumptions. Actual results may differ materially due to a variety of risks and uncertainties. Olympus undertakes no obligation to update or revise any forward-looking statements.

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

Content

1. As a Globally Leading MedTech Company
2. Our Business Fields
3. Company Strategy
4. For a Sustainable Society
5. Company Information
6. Appendix: Olympus History

As a Globally Leading MedTech Company

01

Corporate Philosophy

Our Purpose

Making people's lives healthier, safer and more fulfilling

Our Core Values

Since developing the world's first practical gastrocamera in 1950, Olympus has worked alongside healthcare professionals to contribute to the evolution of endoscopy.

To embody Our Purpose of "Making people's lives healthier, safer and more fulfilling," we are committed to elevating the standard of care to improve outcomes.

Patient Focus, Integrity, Innovation, Impact, and Empathy: our redefined set of five core values. We continuously develop them as a global MedTech company, prioritizing patient safety and quality.

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02



True to Life

”True to Life” is our global brand message that expresses Olympus's commitment to Our Purpose.

At Olympus, we believe everyone should have the opportunity to live life to the full. Every day we are advancing medical technology solutions to help people everywhere fulfill their desires, their curiosity, their dreams, their ambitions, and their lives.

Olympus Locations



28,138

Employees Worldwide*

40

Countries or Regions*

* As of March 2026

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

Our Contribution to Patient Care

53M+

Colonoscopies Performed Worldwide Annually

*Numbers of US, Germany, France, UK, Italy, Spain, Japan, Canada, Poland, South Korea, Australia, India, Russia, China (for CY2022))

Source: Based on the Company's research, as of April 2026

100

Diseases or Conditions Treated

At Olympus we have versatile medical devices with the ability to treat approximately 100* diseases or conditions

Source: Based on the Company's research, as of March 2026

TOP 3

Cancers Treated

Olympus provides products/solutions for lung, colorectum and stomach - Three cancers from the top 5* highest incidence of cancers

*Top 3 highest incidence of cancers excluding breast and prostate cancer Source: GLOBOCAN 2022 https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf

TOP 100

Global Innovator

Since 2012 to 2020, and in 2022 and 2023, Olympus has been awarded as one of the top 100 most innovative companies in the world.

https://clarivate.com/top-100-innovators/

296

Awards

Since 1966, Olympus has been consistently honored with national and international design awards for its innovative product designs*

*As of March 2026

15,000

Patents

Across our product portfolio*

*As of March 2025

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS

Our Business Fields

02

Revenue by Business Divisions/Region



Source: Financial Data for FY2026

Note: We re-aligned our divisional structure from April 2025. The Endoscopic Solutions Division (ESD) and the Therapeutic Solutions Division (TSD) transitioned into the new divisions of Gastrointestinal Solutions Division (GIS) and Surgical & Interventional Solutions Division (SIS).
*Due to rounding, the total may not add up to 100%

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS

Revenue and Operating Profit



69%

Gastrointestinal Solutions

31%

Surgical & Interventional Solutions



*Due to rounding, the total may not add up to 100%

Source: Financial Data for FY2026

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS

Gastrointestinal Solutions Division

Gastrointestinal Endoscopy System

Video endoscopy system

Ultrasound system

GI Endotherapy

CRC devices

HPB devices

Hemostasis

Endoscopic Solutions Ecosystem (Digital Healthcare Solutions)

Intelligent ecosystem operating software platform

AI insights and computer-aided detection/diagnosis

Reprocessing

Endoscope reprocessor

Chemicals, accessories, and peripherals

Medical Services

Repair center

Note: We re-aligned our divisional structure from April 2025. The Endoscopic Solutions Division (ESD) and the Therapeutic Solutions Division (TSD) transitioned into the new divisions of the Gastrointestinal Solutions Division (GIS) and the Surgical & Interventional Solutions Division (SIS). Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions. The Digital Healthcare Solution Products and Technology shown on this slide are Concepts and Solutions Under Development – These products have not been submitted to the FDA and are Not available for Sale in the U.S.A.

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

Surgical and Interventional Solutions Division

Respiratory

Bronchoscopy Systems

Bronchoscopic Devices



Lung Cancer diagnosis/staging

COPD
(Chronic Obstructive Pulmonary Disease)

Urology

Visualization

Stone Management

BPH
(Benign Prostatic Hyperplasia)

Prostate Cancer

BPH + Bladder Cancer

Surgical
(Surgical Endoscopy, Surgical Devices, Ear, Nose, and Throat)

Surgical Endoscopy Systems

Advanced Energy Devices

Surgical Microscope

Integrated Procedure Room Solutions

Rhino-Laryngo Videoscope

Note: We re-aligned our divisional structure from April 2025. The Endoscopic Solutions Division (ESD) and the Therapeutic Solutions Division (TSD) transitioned into the new divisions of the Gastrointestinal Solutions Division (GIS) and the Surgical & Interventional Solutions Division (SIS).
Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.
The Digital Healthcare Solution Products and Technology shown on this slide are Concepts and Solutions Under Development – These products have not been submitted to the FDA and are Not available for Sale in the U.S.A.

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS

Corporate Strategy

03

Global Trends Show Increasing Demand for Endoscopy Procedures, Underpinned by Macroeconomic Factors and the Need for Better Care

Global demand drives 5% annual growth of endoscopy-enabled care[1]

- Aging populations (>40% of the global population over 60)
- Growing prevalence in GI, urological, and lung cancers
- Broadening access to care

Opportunity for further growth

- Accelerating access in underserved geographies
- Scaling established procedures like ERCP and ESD
- Expanding into adjacent disease areas and procedures that today rely on more invasive methods



1. Market value growth base on AcuityMD, Ministries of Health, IQVIA FlexView MedTech, Olympus China primary market research 2. Based on Olympus' market insights derived from IQVIA FlexView MedTech
3. Assumes global per capita utilization matches US/EU/Japan/China levels

Estimates and market projections are based on internal analyses and third-party data sources. Actual market growth and procedure volumes may differ.

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

A New Vision for Endoscopy-Enabled Care Is Needed to Deliver Against Healthcare Needs and Opportunities

Patients

Endoscopy that's advanced and less invasive brings clarity and comfort.

- New technologies may support earlier identification and clinical assessment, may provide additional information to support clinical decision-making
- Same-day results ease anxiety
- Less invasive approaches may support faster recovery

Clinicians

Endoscopy made safer, smarter, and more consistent

- Tech can lighten manual and cognitive load
- Automation can free time for clinical decisions and patient communication
- Complex procedures can become consistent and reproducible
- Nurses manage data for continuity of care

Administrators

Advanced technology can drive efficiency and lowers costs

- Predictive maintenance and smart fleet management can increase uptime
- Single-use and modular tools can simplify logistics
- Streamlined operations can cut costs and help support compliance with standards

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

Olympus Is Positioned to Deliver on That Future

A Backbone of Scalable Endoscopy

Large installed base of interoperable towers for scalable, integrated workflows, including service/support and training available to support improved uptime



Advanced Endoscopes and Therapeutic Devices

Broad portfolio of scopes and therapeutic devices to detect, diagnose, and treat disease across major specialties and care settings

Smart Technologies Driving the Future

AI*, robotics, and workflow management designed to support procedural efficiency and workflow optimization

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

*AI-enabled technologies are intended to support, and not replace, independent clinical judgment.

OLYMPUS

Olympus Is Accelerating Investments in the Endosuite[1] of the Future

Integrate AI into the endoscopy ecosystem

OLYSENSE CAD/AI launched commercially (US and selected EU). By FY28 and 31, aiming to integrate OLYSENSE in 5% and 25% of our global installed base, respectively.

Build robotic endoluminal solutions

Swan EndoSurgical and other partnerships lay the foundation for establishing new GI care standards, designed to support procedural efficiency and broaden access to advanced therapeutic techniques.

Expand advanced diagnostic and therapeutic portfolio

Develop, partner, and acquire advanced solutions that are designed to detect, diagnose, and treat disease, and equip healthcare professionals to fight disease across our clinical and disease focus areas.

[1] A solution that could extend the reach of endotherapies while improving the patient experience, using artificial intelligence (AI) and other digital tools and technologies. AI-enabled technologies are intended to support, and not replace, independent clinical judgment. Note: Products shown may not be available in all regions. As with any medical device, careful consideration should be given to all applicable labeling, including potential risks and benefits associated with the product.

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS

Envisioning the Future of Endoscopy-Enabled Care

Better care

Detect diseases earlier

Same day diagnosis, staging, and treatment

Expanding minimally-invasive therapeutic options, reducing reliance on surgery

Enabling more diseases to be treated endoscopically

Driving efficiencies through smart workflows

Powered by an integrated ecosystem

Ecosystem of cloud connected hardware, devices, software and services, paired with cutting edge optics, AI and robotics

Integrated data to generate individualized and predictive insights at the point of care

Visionary concepts for future endoscopy-enabled care. Future capabilities are under development and may not become commercially available. AI-enabled technologies are intended to support, and not replace, independent clinical judgment.

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS

Where Purpose Meets Performance: Shaping the Future of Endoscopy-Enabled Care

OUR PURPOSE

Making people's lives healthier, safer and more fulfilling

OUR STRATEGIC PILLARS

Innovation-Driven Growth

Lead the next wave of innovation & expand to faster-growing segments

- Fortify portfolio through focused investments
- Shape the future of endoscopy through OLYSENSE and robotics
- Enhance performance in China and set direction for emerging markets
- Drive M&A tuck-ins in close adjacencies

Simplicity

Simplify Olympus to move faster and operate smarter

- Build a lean, division-led operating model and governance at competitive cost base
- Further harmonize end-to-end processes and leverage AI
- Improve innovation model for continuous and accelerated release of new products
- Build resilient, flexible and efficient manufacturing and supply chain

Accountability

Instill a high-performance culture of ownership and execution

- Embrace a patient-first mindset, embedding quality & safety into every step of work
- Deliver ESG commitments
- Establish a global Olympus management system

OUR FINANCIAL ASPIRATIONS FY27-29

Revenue[1]	Op Margin[2]	EPS CAGR[2]
~5 %	~100 bps	>10 %
Growing at 5% by FY29	Year-on-year growth from FY26	From FY2026

[1] Constant Currency basis [2] Adjusted for extraordinary items: Exclude "Other income/expenses, no adjustment will be made for the impact of exchange rate fluctuations, actual exchange rate will be used.
Financial aspirations are management goals and not guarantees of future performance. Actual results may differ materially.

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS

For a Sustainable Society

04

Common Topics in ESG*



Environment

- Climate Change/Carbon Neutrality
- Circular Economy
- GHG Emissions
- Water & Waste Management

Social

- Human Rights
- Inclusion
- Workplace Safety
- Healthcare Access & Outcome

Governance

- Corporate Risk Management
- Management Structure
- Reporting Transparency

*Major examples only / not limited

Sustainability

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS

ESG Six Focus Areas and Materiality Topics for Contributing to Solutions to Social Issues

Healthcare Access and Outcome

Contribution to health equity and access

Compliance, Product Quality and Safety

Quality and safety in product, service and solution

Responsible Supply Chain

Supply chain risk mitigation and resilience

Healthy Organization

Inclusion

Carbon Neutral Society and Circular Economy

Circularity through product stewardship, carbon emissions
(Scope 1, 2 and 3)

Corporate Governance

Corporate governance and reporting transparency

Materiality Stories Impact Action Stories

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS

Company Information

05

Company Outline

Company Name	Olympus Corporation
Market	Tokyo Stock Exchange, Prime Market (7733)
Established	October 12, 1919
Head Office	2951 Ishikawa-machi, Hachioji-shi, Tokyo 192-8507, Japan
Share Capital	124.643 billion yen (As of March 31, 2026)
Consolidated Revenue	1,010.7 billion yen (Fiscal year ended March 31, 2026)
Consolidated Headcount	28,138 (As of March 31, 2026)
Corporate Website	https://www.olympus-global.com/

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

Key Overseas Sites

U.S.A.: Manufacturing sites: 2 sites

Center Valley (HQ)

Brooklyn Park
Product types: Surgical energy devices

Redmond
Product types: Bronchoscopy devices;
Spiration valve system

Westborough (Surgical and Interventional Solutions Business HQ)

Europe: 5 Manufacturing sites

Germany: Hamburg (HQ)

Product types：Surgical rigid speculum

Germany: Berlin
Product types：High frequency generator

Czech Republic: Přerov
Product types: Urological devices

United Kingdom: Plymouth
Product types: Medical related products

United Kingdom: Southend-on-Sea
Product types：Endoscope peripheral equipment (trolley, insufflator)

Asia: Manufacturing sites: 2 sites

China: Beijing (HQ)

Suzhou
Endoscope assembly

Hong Kong (HQ)

Vietnam
Product types：Treatment devices

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

Domestic Sites and Production Sites



Aizu Olympus Corporation

Product types: Scopes

Nagano Olympus Corporation

Product types: Medical related parts

Service Operation Center Nagano

Aomori Olympus Corporation

Product types: Medical treatment devices, Surgical energy devices

Shirakawa Olympus Corporation

Product types: Power supply and light source devices, Imaging processing devices, Ultrasound endoscopes

Service Operation Center Shirakawa

Olympus Corporation (Global Headquarters)

Olympus Medical Systems Corporation (Hinode Factory)

Product types: Medical products and prototypes

- Manufacturing and repair
- Sales and marketing

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

Executive Officers

Bob White
Director, Representative Executive Officer, President and Chief Executive Officer

Simone Berger
Executive Officer and Chief Human Resources Officer

Keith Boettiger
Executive Officer and Gastrointestinal Solutions Division Head

John de Csepel
Executive Officer and Chief Medical Officer

Gabriela Kaynor
Executive Officer and Chief Strategy Officer

Seiji Kuramoto
Executive Officer and Surgical and Interventional Solutions Division Head

Syed Naveed
Executive Officer and Chief Technology Officer

Michael Parenti
Executive Officer and Chief Financial Officer

David Shan
Executive Officer and Chief Manufacturing and Supply Officer

Brian Barry
Executive Officer and Chief Quality Officer

Neil Boyden Tanner
Executive Officer and Global General Counsel

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS

Appendix:
Olympus History

06

Olympus History

1919

Founding of **Olympus** by Takeshi Yamashita under the company name **Takachiho Seisakusho**; established in Tokyo, Japan, for domestic production of microscopes.

1920

Sales launch of **Asahi** microscope.

1936

Launch of first Olympus camera, the **Semi-Olympus I**, after development of Zuiko photographic lenses.

1949

Renaming of company to **Olympus Optical Co., Ltd.**

1950

Development of world's **first practical** gastrocamera.

1964

Start up of **Olympus Optical Co.** in Hamburg, Germany, as Olympus' European headquarters.

1968

Establishment of **Olympus Corporation of America** as a sales subsidiary for microscopes and medical equipment in the United States.

1975

Collaboration with Winter & Ibe GmbH to produce surgical rigid medical endoscopes, with Olympus supplying the optical systems.

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

Olympus History

1985

Introduction of Olympus' endoscopic video information system

Renaming of company to **Olympus Corporation.**

2003

2011

Formation of a third-party committee by Olympus to investigate prior concealment of company losses.

Announcement of Olympus' medium-term vision, designed to realize a "New Olympus" and take the Company "Back to Basics."

2012

2019

Celebration of Olympus **100th Anniversary** Transformation Plan "**Transform Olympus**", Corporate Strategy Announced.

Launch of **EVIS X1™** System for EMEA and some Asian countries/ regions

2020

2021

Transfer of **Imaging Business**

Transfer of **Scientific Business**

2023

2024

Relocating from Shinjuku to Hachioji. Transforming into a **Global Headquarters**.

Olympus Corporation No data copy / No data transfer permitted / August 2026 Ver.3/ LCR59734V02

OLYMPUS